Tazemetostat blocks the action of a protein called EZH2. Some patients with malignant mesothelioma produce large amounts of the EZH2 protein, which encourages abnormal growth and development of mesothelial cells. By blocking EZH2, tazememostat is expected to lead to the death of the mesothelial cells and thus reduce the growth of the cancer.<\/p>\n
The US FDA approved TAZEMETOSTAT for treating patients aged above 16 years with metastatic or locally advanced epithelioid sarcoma who cant undergo complete resection. It should be taken as 800 mg taken orally twice daily with or without food. It can increase the risk of developing secondary cancers like lymphoma, leukemia, etc. It can cause fetal harm. So, patients should use effective non-hormonal contraception. Common side effects reported with TAZEMETOSTAT are pain, fatigue, nausea, decreased appetite, vomiting etc.<\/p>\n
To access tazemetostat tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n
Tazverik (tazemetostat) is a medication used for the treatment of epithelioid sarcoma that is locally advanced (when the cancer is growing outside of the organ, but has not yet spread) or metastasized (when cancer cells have spread to other parts of the body) and that cannot be completely removed by surgery, and for relapsed or refractory follicular lymphoma.<\/p>\n
Facts about tazemetostat tablets<\/strong><\/p>\n Disease Indications-Soft Tissue Sarcoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “tazemetostat tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Epizyme inc.
\nUsage-Oral
\nMedicine Approved By-Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n